课题基金 / 基金详情

Tufts Clinical and Translational Science Institute (N3C Supplement)

Tufts Clinical and Translational Science Institute (N3C Supplement)
塔夫茨临床与转化科学研究所(N3C 增刊)
批准号:
10172199
负责人:
Harry P. Selker
金额:
$10.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-05-01 至 2023-04-30

项目摘要

项目成果

Harry P. Selker的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY Tufts Clinical and Translational Science Institute (Tufts CTSI) is based on the conviction that authentic involvement of the entire spectrum of clinical and translational research (CTR) is critical to fulfilling the promise of biomedical science for meeting the public's needs. This includes not only from translation from bench to bedside (T1 translation), but also, crucially for having health impact, translation into effective clinical practice (T2), care delivery and public health (T3), and health policy (T4). Advances on all of these fronts is increasingly dependent on making effective use of scientific data from multiple domains. The COVID-19 global emergency presents both an immediate challenge and an opportunity to progress on important data sharing aims emphasized by NIH. In response, NCATS and the Centers for Translational Science Award (CTSA) hubs, several HHS agencies, and other partnering organizations have committed to developing a next-generation repository for clinical data related to COVID-19, the National COVID Cohort Collaborative (N3C), as a means of accelerating global research into the disease and aiding the development of diagnostics, therapeutics, and effective vaccines. The N3C initiative's goal of improving the efficiency and accessibility of analyses with clinical data is consistent with the primary informatics objectives of Tufts CTSI, which am to reduce barriers to the integration of healthcare and research by providing innovative systems, data repositories, and analytical tools, and by enabling greater exchange and collaboration through interoperability, standardization, and resource sharing. In- line with shared objectives, in this supplement we seek to contribute to the N3C initiative as a data provider and thought partner through the following specific aims: (1) continue to play an important role providing tools and resources for N3C's analytics platform; and (2) ensure Tufts CTSI's Informatics Program has sufficient staff and technical resources to continue to provide COVID-specific patient data from our hub to the N3C repository.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Tufts Clinical and Translational Science Institute (Clinical Trial Design Labs Supplement)
  • 批准号:
    10844980
  • 项目类别:
  • 资助金额:
    $97.51万
  • 财政年份:
    2023
  • 负责人:
    Harry P. Selker
  • 依托单位:
Tufts Clinical and Translational Science Institute
  • 批准号:
    10622002
  • 项目类别:
  • 资助金额:
    $1139.42万
  • 财政年份:
    2023
  • 负责人:
    Harry P. Selker
  • 依托单位:
Tufts Clinical and Translational Science Institute
  • 批准号:
    9816143
  • 项目类别:
  • 资助金额:
    $13.45万
  • 财政年份:
    2018
  • 负责人:
    Harry P. Selker
  • 依托单位:
Tufts Clinical and Translational Science Institute
  • 批准号:
    10159334
  • 项目类别:
  • 资助金额:
    $943.36万
  • 财政年份:
    2018
  • 负责人:
    Harry P. Selker
  • 依托单位:
国内基金
海外基金
CEACAM5调控Galectin-9介导的CD4+T细胞极化在COVID-19肠屏障损伤的作用机制研究
  • 批准号:
    82370569
  • 项目类别:
    面上项目
  • 资助金额:
    49万元
  • 批准年份:
    2023
  • 负责人:
    李啸峰
  • 依托单位:
COVID-19疫情对我国儿童生长发育影响的异质性研究
  • 批准号:
    42371429
  • 项目类别:
    面上项目
  • 资助金额:
    52.00万元
  • 批准年份:
    2023
  • 负责人:
    张知新
  • 依托单位:
传染病模型的稳态切换过程研究及其在治疗COVID-19中的应用
  • 批准号:
    LQ23A010016
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2023
  • 负责人:
    罗敏
  • 依托单位:
“湿漫膜原”视角下研究加味达原饮重塑COVID-19“免疫炎症稳态”的分子机制:TLR4介导IRF3/NF-κB通路串扰
  • 批准号:
    82374291
  • 项目类别:
    面上项目
  • 资助金额:
    48万元
  • 批准年份:
    2023
  • 负责人:
    张传涛
  • 依托单位: